PetMed Express Inc (PETS)
Official siteHEALTHCARE • PHARMACEUTICAL RETAILERS • NASDAQ
Market Cap: $19.96M
Last updated: Nov 17, 2026 at 4:10 PM ET
PetMed Express Inc (PETS) Statistics
PetMed Express (PETS) has a market cap of $19.96M and an enterprise value of $8.54M. It holds $11.42M more cash than debt, 57.21% of its market cap. Revenue fell 19.17% over the last 12 months from the 12 months before.
Total Valuation
Enterprise value is 57.21% below the market cap, as cash exceeds debt.
| Market Cap | $19.96M |
|---|---|
| Enterprise Value | $8.54M |
| Latest price (Nov 17, 2026) | $0.90 |
Key Dates
The next earnings report is expected on Feb 3, 2027, covering the quarter ending Dec 31, 2026.
| Next Earnings Date | Feb 3, 2027 (expected) |
|---|---|
| Last Earnings Date | Nov 10, 2026 |
| Fiscal Year End | March |
Valuation Ratios
Sales and book value multiples are 0.1x and 1.1x. Its year-end P/S ranged from 0.4x to 3.4x from 2016 to 2024.
| P/S Ratio | 0.1x |
|---|---|
| P/B Ratio | 1.1x |
| P/TBV Ratio | 2.9x |
Price Statistics
The stock is down 55.02% over 52 weeks and trades 31.30% below its 50-day average.
| Beta (1Y) | 0.89 |
|---|---|
| 52-Week Change | -55.02% |
| 1-Month Change | -21.78% |
| 3-Month Change | -49.18% |
| 6-Month Change | -59.30% |
| 5-Year Change | -95.81% |
| 10-Year Change | -94.01% |
| Total Return (1Y) | -55.02% |
| Total Return (3Y CAGR) | -50.94% |
| Total Return (5Y CAGR) | -49.11% |
| Max Drawdown (1Y) | -76.98% |
| Max Drawdown (3Y) | -88.37% |
| Sharpe Ratio (1Y) | -0.93 |
| Correlation with SPY (1Y) | 0.16 |
| 50-Day Average | $1.31 |
| 200-Day Average | $1.98 |
| 52-Week Range | $0.85 to $4.10 |
| RSI (14 Days) | 19.8 |
| Average Volume (20 Days) | 121.80K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 0.60x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 0.60x |
|---|---|
| Quick Ratio | 0.45x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is -161.27% over the last 12 months, against a 5-year average of -38.64%.
| Return on Equity (ROE) | -161.27% |
|---|---|
| Return on Assets (ROA) | -45.78% |
| ROE (5Y Average) | -38.64% |
| ROA (5Y Average) | -13.14% |
| Asset Turnover | 2.01x |
| Inventory Turnover | 15.67x |
| Receivables Turnover | 104.10x |
| Cash Conversion Cycle | -17 days |
Scores
PETS has an Altman Z-Score of 1.00, in the distress zone below 1.81, and a Piotroski F-Score of 2 of 9, in the weak band of 0 to 2.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 1.00 |
|---|---|
| Altman Z Zone | Distress |
| Piotroski F-Score | 2 of 9 |
| Piotroski Strength | Weak |
Income Statement
Revenue was $160.26M over the last 12 months.
| Revenue | $160.26M |
|---|---|
| Revenue Growth (YoY) | -19.17% |
| Gross Profit | $44.53M |
| Operating Income | -$28.81M |
| Pretax Income | -$27.26M |
| Net Income | -$27.19M |
| EBITDA | -$18.60M |
| Reported EPS (TTM) | -$1.28 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 28.38% of the $59.40M in total assets.
| Cash and Equivalents | $11.42M |
|---|---|
| Total Debt | $0 |
| Net Cash | $11.42M |
| Net Cash Per Share | $0.54 |
| Working Capital | -$17.02M |
| Shareholder Equity | $16.86M |
| Book Value Per Share | $0.80 |
| Tangible Book Value | $6.55M |
| Tangible Book Per Share | $0.31 |
| Total Assets | $59.40M |
| Total Liabilities | $42.54M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.97M of capital spending, operating cash flow left -$24.66M of free cash flow.
| Operating Cash Flow | -$22.69M |
|---|---|
| Capital Expenditures | $1.97M |
| Free Cash Flow | -$24.66M |
| FCF Per Share | -$1.14 |
| Depreciation and Amortization | $9.16M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is -17.98%, against a 5-year average of -5.01%.
| Gross Margin | 27.79% |
|---|---|
| Operating Margin | -17.98% |
| Pretax Margin | -17.01% |
| Net Margin | -16.97% |
| EBITDA Margin | -11.61% |
| FCF Margin | -15.39% |
| Gross Margin (5Y Average) | 29.72% |
| Operating Margin (5Y Average) | -5.01% |
| Net Margin (5Y Average) | -5.71% |
Growth
Revenue fell 10.24% a year over 3 years.
| Revenue Growth (3Y CAGR) | -10.24% |
|---|---|
| Revenue Growth (5Y CAGR) | -10.02% |
Peer Position
Against 8 similar companies, PETS has the lowest P/S.
P/S RatioPeer median 4.4x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +246.13%
| P/S Ratio | 0.1x vs 4.4x median |
|---|---|
| Revenue Growth (Trailing 4 Quarters, YoY) | -19.17% vs +246.13% median |
Analyst Forecast
Consensus estimates put revenue growth at -7.70% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | -7.70% |
|---|
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Undervalued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About PETS
What is PETS's market cap?
PetMed Express has a market cap of $19.96M. Its enterprise value, which adds debt and subtracts cash, is $8.54M.
How many shares of PETS are outstanding?
PetMed Express has 21.07M shares outstanding. The count is up 0.88% from a year earlier.
Does PETS pay a dividend?
No. PetMed Express does not pay a dividend.
How much debt does PETS have?
PetMed Express has $0 of total debt and $11.42M of cash and equivalents, a net cash position of $11.42M.
PETS pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors